Susan Kalled, PhD, joined Compass in May 2021 bringing over 20 years of scientific, strategic and operational leadership experience advancing programs from early-stage discovery through clinical development, specializing in autoimmunity, inflammation, and rare disease. Prior to joining Compass, Dr. Kalled was Vice President of Biology at Q32 Bio where she was responsible for research functions and data generation that helped secure successful Series A and B funding rounds. Prior to Q32, Susan was Head of External Sciences at Shire where she built the external sciences group that scouted for and funded promising academic research for potential in-licensing managed budgets and pipelines that spanned multiple modalities and therapeutics areas, including but not limited to, gastrointestinal/metabolic, genetic diseases, immunology, complement biology, and oncology. Earlier in her career, Susan held multiple positions of increasing responsibility at Biogen, where she was the Therapeutic Area Lead for translational medicine and a Principal Scientist and Project Leader in Immunobiology. Susan is a member of American Association for the Advancement of Science, American Association of Immunologists, and New York Academy of Sciences.
Susan received her PhD in Immunology from Tufts University and a Bachelor of Arts in Microbiology from the University of New Hampshire.